What Stood Out at IMS 2026? Five Myeloma Experts Weigh In

Every year, the International Myeloma Society (IMS) Annual Meeting brings together the field's leading clinicians and researchers to share the data shaping the future of multiple myeloma care. In this episode of The OncoloGIST, we hear directly from five experts about the findings and discussions that stood out most.

Joining us are Sagar Lonial, MD; Pieter Sonneveld, MD, PhD; Ja Min Byun, MD, PhD; Leo Rasche, MD; and Giada Bianchi, MD. Each shares the takeaways that resonated with them, offering a firsthand look at what mattered most from the meeting.

Two topics came up repeatedly. The first was the CERVINO trial, which several of our guests singled out as one of the more compelling presentations at IMS 2026. They discuss what the findings could mean for how clinicians think about treatment strategies and where the research may be headed next.

The second was the long-term follow-up from the PERSEUS study. As the evaluation of daratumumab-based quadruplet therapy in the frontline setting matures, our experts reflect on what extended follow-up adds to the conversation, from durability of response to how these results may inform real-world decision-making for patients with newly diagnosed disease.

Beyond individual studies, the conversation touches on broader themes from the meeting, including how emerging data are influencing clinical practice, where unmet needs remain, and what the community should be watching in the year ahead.

Whether you attended IMS 2026 or are catching up on the highlights, this episode offers a concise, expert-driven recap of the data and ideas that defined the meeting. Watch now to hear what these leading myeloma specialists consider the key takeaways from IMS 2026.